27 Jul 2016

UCB continues to deliver on its growth strategy

Read More
22 Jul 2016

UCB and Amgen submit biologics license application for Romosozumab to the U.S. FDA

Read More
4 Jul 2016

UCB and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VIMPAT®) as adjunctive therapy in the treatment of partial-onset seizures in adult patients with epilepsy

Read More
9 Jun 2016

UCB’s bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis

Read More
7 Jun 2016

UCB commitment to addressing real world patient needs on display at the Annual European Congress of Rheumatology (EULAR 2016)

Read More
30 May 2016

BRIVIACT® now available in U.S. pharmacies for epilepsy patients living with partial-onset seizures

Read More
29 May 2016

Positive VIMPAT® (lacosamide) monotherapy Phase III trial results presented at European Academy of Neurology Congress

Read More
28 Apr 2016

UCB's shareholder meeting today

Read More
25 Apr 2016

UCB First Three Months Interim Report 2016:

Read More
1 Apr 2016

Amgen and UCB present positive data at ENDO 2016  comparing romosozumab with teriparatide

Read More
Subscribe to